-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 B6+KfnMAPiH4wEeJZJ7uFHiisCGIz76VxrikRz8xluSlAbS/uAp/zxMSG95Jp53s
 TfHKs/rXWI2xXUcGYPFNNg==

<SEC-DOCUMENT>/in/edgar/work/0000920148-00-000054/0000920148-00-000054.txt : 20001024
<SEC-HEADER>0000920148-00-000054.hdr.sgml : 20001024
ACCESSION NUMBER:		0000920148-00-000054
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20001023
ITEM INFORMATION:		
FILED AS OF DATE:		20001023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LABORATORY CORP OF AMERICA HOLDINGS
		CENTRAL INDEX KEY:			0000920148
		STANDARD INDUSTRIAL CLASSIFICATION:	 [8071
]		IRS NUMBER:				133757370
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231
</COMPANY-DATA>

		FILING VALUES:
			FORM TYPE:		8-K
			SEC ACT:		
			SEC FILE NUMBER:	001-11353
			FILM NUMBER:		744279
</FILING-VALUES>

			BUSINESS ADDRESS:	
				STREET 1:		358 S MAIN ST
				STREET 2:		4225 EXECUTIVE SQ STE 800
				CITY:			BURLINGTON
				STATE:			NC
				ZIP:			27215
				BUSINESS PHONE:		3362291127
</BUSINESS-ADDRESS>

				MAIL ADDRESS:	
					STREET 1:		358 S MAIN ST
					STREET 2:		4225 EXECUTIVE SQ SUITE 800
					CITY:			BURLINGTON
					STATE:			NC
					ZIP:			27215
</MAIL-ADDRESS>

					FORMER COMPANY:	
						FORMER CONFORMED NAME:	NATIONAL HEALTH LABORATORIES HOLDINGS INC
						DATE OF NAME CHANGE:	19940314
</FORMER-COMPANY>
</FILER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.txt
<TEXT>




      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
                      October 23, 2000
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission          (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                   Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)

<PAGE>

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit  Summary information of the Company dated
      October 23, 2000.



<PAGE>
                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                        (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: October 23, 2000


<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-20
<SEQUENCE>2
<FILENAME>0002.txt
<TEXT>


This  information contains forward-looking statements  which
are  subject  to change based on various important  factors,
including  without limitation, competitive  actions  in  the
marketplace  and adverse actions of governmental  and  other
third-party   payors.   Further  information  on   potential
factors that could affect the Company's financial results is
included  in  the  Company's Form 10-K for  the  year  ended
December 31, 1999 and subsequent filings.

Overview of LabCorp
 - Nationwide network of 25 primary testing facilities and
   900
   patient service centers
 - Conducts tests on 260,000 specimens daily
 - Offers more than 2,000 test procedures
 - Serves over 100,000 physicians and other health care
   providers
 - 8,000 employees nationwide


The Clinical Laboratory Testing Market
US market is approximately $30-32 billion

CLINICAL LABORATORY TESTING           INDEPENDENT CLINICAL LABORATORIES

Hospitals               49%           All others         86%
Physician Offices       13%           LabCorp($1.699b)   14%
Independent Clinical Labs  39%

Source: Lab Industry Reports  2/99 & 1999 YE revenue
for LabCorp


Strategic Goals

1.    Strengthen  standing  as  a  national  laboratory  that
      provides a full range of laboratory services

2.    Leverage   broad-reaching  infrastructure   to   expand
      leadership position in esoteric testing

2000 Strategic Approach
 - Maintain national coverage for all key customers
 - Expand upon leading position in Genomic testing
 - Evaluate appropriate acquisition candidates
 - Continue to move to single billing system
 - Expand relationships with key health care /
 - e-commerce providers
 - Develop  strategy  to tap full potential  of  LabCorp's
   extensive database

<PAGE>
<TABLE>
                   Financial Performance
           Price & Volumes:  Trends by Payor Type
<CAPTION>
                                               *Pro-Forma           9/30/00
                            1998                   1999           YTD ACTUAL
                       PPA    Accessions    PPA   Accessions     PPA  Accessions
                        $      millions      $     millions       $     millions
                      ----------------    ------------------    ---------------
<S>                   <C>       <C>          <C>       <C>      <C>      <C>
Client   (Physicians)   22.21    25.9         21.46     27.0     22.29    20.4
Patient                 79.62     2.2         92.56      2.3    102.23     1.6
Third   Party           29.13    12.2         27.75     11.7     29.26     8.3
(MC/MD/Insurance)
Managed Care
   -  Capitated          9.88     9.1         10.06      8.4      9.30     7.7
   -  Fee for service   40.43    10.3         39.28     12.7     41.41    12.0
                       ------   -----        ------     ----    ------    ----
Total                   26.09    19.4         27.68     21.1     28.93    19.7
                       ------   -----        ------     ----    ------    ----

LabCorp   Total        $27.01    59.7        $27.35     62.1    $28.64    50.0
</TABLE>
*(1) Adjusted accessions for Client
 (2) Reported PPA for Client was $22.36 with 25.9
     accessions
 (3) Reported  PPA  for  Company  was  $27.84  with   61.0
     accessions

<TABLE>
                                   Financial Performance
                             Revenue Analysis by Business Area
<CAPTION>
                  YTD  SEPT 1999                  YTD  SEPT 2000
          REVENUE     ACCN    %ACCNS   PPA    REVENUE    ACCNS  %ACCNS    PPA
         $Millions    000    to total   $     $Millions   000  to total    $
         ---------    -----  --------  ----   ---------  ----  -------- ------
<S>      <C>         <C>      <C>     <C>      <C>       <C>     <C>     <C>
CMBP        77.3      761.1    1.7%   101.57     94.6     858.5   1.7%   110.25
Powell
 Esoteric  117.1    2,610.6    5.7%    44.85    135.0   2,964.4   5.9%    45.52

Core     1,081.6   42,649.0   92.7%    25.36  1,203.7  46,218.3   92.4%   26.04
         -------   --------  -----     -----  -------  --------  -----    -----
Total    1,276.0   46,020.7  100.0%    27.73  1,433.3  50,041.2  100.0%   28.64
         =======   ========  ======    =====  =======  ========  =====    =====

                     99 VS 00
                         PPA
                     Incr/(Decr)
                     -----------
CMBP                     8.5%
Powell
 Esoteric                1.5%

Core                     2.7%
                         ---
Total                    3.3%
                         ===
</TABLE>

Year-End Financials
                           12-31-97        12-31-98      12-31-99
                           --------        --------      --------
     Revenue                1,579.9         1,612.6       1,698.7
     Operating Expense      1,473.8         1,485.0       1,549.0
                            -------         -------       -------
     Operating Income         106.1           127.6         149.7
                            -------         -------       -------
                 Margin         6.7%            7.9%         8.8%
     EBITDA                   191.2           210.4        233.4
                            =======         =======       ======
                 Margin        12.1%           13.0%        13.7%
                            -------         -------       ------
     Bad Debt % to revenue      9.6%           10.2%        11.3%
                            -------         -------       ------
     DSO                         79              83           74
                            -------         -------       ------



<PAGE>
THIRD QUARTER OPERATING RESULTS

                                         9/30/99           9/30/00
                                         -------           -------
           Revenue                        428.6             488.1
           Operating Expense              388.5             418.8
                                          -----             -----
           Operating Income                40.1              69.3
                                          -----             -----
                Margin                      9.4%             14.2%
           EBITDA                          60.3              92.1
                                           ====              ====
                Margin                     14.1%             18.9%
                                           ----              ----
           Bad Debt % to revenue           11.4%             10.2%
                                           ----              ----
           DSO                               76                70



2000 THIRD QUARTER ACHIEVEMENTS

 - Increased revenues 13.9% (volume 9.4%; price 4.5%)
 - Increased EBITDA 53%
 - Increased diluted EPS 194%
 - Completed acquisition of National Genetics Institute
   7/31/00.


NINE MONTH OPERATING RESULTS

                                    YTD 9/99         YTD 9/00
                                    --------         --------
      Revenue                       1,276.0          1,433.3
      Operating Expense             1,159.4          1,235.3
                                    -------          -------
      Operating Income                116.6            198.0
                                    -------          -------
           Margin                       9.1%            13.8%
      EBITDA                          178.9            263.5
                                     ======          =======
           Margin                      14.0%            18.4%
                                     ------          -------
      Bad Debt % to revenue            11.6%            10.2%
                                     ------          -------
      DSO                                76               70


2000 Nine Months YTD Achievements
 - Increased revenues 12.3% (volume 8.9%; price 3.4%)
 - Increased EBITDA 47%
 - Increased diluted EPS 142%
 - Increased operating cash flow 38%
 - DSO reduced 4 days from year end 1999 to 70 days
 - Reduced interest rate to LIBOR plus 37.5 basis points


Financial Goals for 2000
 - Increase overall revenues by approximately 12%
  -  Increase  EBITDA  margins  to  approximately  17.5%  of
revenue
 - Increase diluted EPS to approximately $3.20 per share
 - Reduce debt by approximately $90 million
 - Lower DSO to approximately 69 days



Financial Goals for 2001
 - Increase overall revenues 10-12%
 - Increase EBITDA margins to approximately
   20-21% of sales
 - EPS growth of approximately 50% compared to 2000
 - Reduce debt by approximately $132 million
 - Lower DSO to the mid 60's range

Opportunity for Investors
 - A proven strategy for growth
 - LabCorp is a pioneer in identifying and commercializing
   innovative technologies the first to fully embrace
   molecular diagnostics
 - LabCorp's national infrastructure connects large scale
   proficiency with wide scale technological expertise
 - New advances in scientific research will generate growth
   and demand for molecular testing


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
